Maintenance niraparib fails to improve PFS in advanced urothelial cancer

The Meet-URO12 trial of maintenance niraparib in advanced urothelial cancer patients without progression after first-line chemotherapy failed to meet its primary endpoint of improvement in progression-free survival (PFS). Homologous recombination deficiency (HRD) is present in 10–25% of advanced urothelial carcinomas and sensitises cancer cells to both platinum-based chemotherapy and PARP inhibitors [1,2]. This offers a rationale for maintenance therapy with a PARP inhibitor in patients with advanced urothelial carcinoma who obtained an objective response or stable disease with first-line platinum-based chemotherapy. Meet-URO12 (NCT03945084) is a phase 2, prospective, randomised, open-label, multicentre study conducted in patients with locally advanced or metastatic urothelial carcinoma who show no evidence of progression after 4–6 cycles of first-line plati...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 8 April, 20228 April, 2022